Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon

• Status: Completed
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to investigate the efficacy and safety of EGb 761® in patients with the primary Raynaud phenomenon, with regards to the frequency, duration and severity of vasospastic attacks.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VSM Geneesmiddelen b.v.

Criteria

Inclusion Criteria:

• Primary Raynaud´s phenomenon

• History of episodic digital or toe pallor

• Duration of Raynaud´s phenomenon at least 2 years

• Suffering form regular occuring attacks prior to enrolment

Exclusion Criteria:

• Secondary Raynaud´s phenomenon

• Connective tissue disease

• Large vessel disease

• Cryoglobulinemia, cold agglutinins disease, thrombocytosis

• Concomitant pharmacological treatment with effects on the vasculature

• Pregnancy or lactation

• Severe internal or systemic disease